These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31529318)

  • 1. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
    Wang EQ; Bukowski JF; Yunis C; Shear CL; Ridker PM; Schwartz PF; Baltrukonis D
    BioDrugs; 2019 Oct; 33(5):571-579. PubMed ID: 31529318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
    Ridker PM; Tardif JC; Amarenco P; Duggan W; Glynn RJ; Jukema JW; Kastelein JJP; Kim AM; Koenig W; Nissen S; Revkin J; Rose LM; Santos RD; Schwartz PF; Shear CL; Yunis C;
    N Engl J Med; 2017 Apr; 376(16):1517-1526. PubMed ID: 28304227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
    Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC;
    N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　- Results From a Randomized, Placebo-Controlled, Dose-Ranging Study.
    Yokote K; Kanada S; Matsuoka O; Sekino H; Imai K; Tabira J; Matsuoka N; Chaudhuri S; Teramoto T
    Circ J; 2017 Sep; 81(10):1496-1505. PubMed ID: 28539539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bococizumab for the treatment of hypercholesterolaemia.
    Ferri N; Corsini A; Sirtori CR; Ruscica M
    Expert Opin Biol Ther; 2017 Feb; 17(2):237-243. PubMed ID: 28060539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
    Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
    J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study.
    McCush F; Wang E; Yunis C; Schwartz P; Baltrukonis D
    AAPS J; 2023 Sep; 25(5):85. PubMed ID: 37658997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.
    Strat AL; Ghiciuc CM; Lupuşoru CE; Mitu F
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):228-32. PubMed ID: 27483697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
    Chackerian B; Remaley A
    Curr Opin Lipidol; 2016 Aug; 27(4):345-50. PubMed ID: 27389630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
    Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
    Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
.
    Yokote K; Suzuki A; Li Y; Matsuoka N; Teramoto T
    Int J Clin Pharmacol Ther; 2019 Dec; 57(12):575-589. PubMed ID: 31549625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.